Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHL · Real-Time Price · USD
4.230
+0.330 (8.46%)
At close: Mar 9, 2026, 4:00 PM EDT
4.250
+0.020 (0.47%)
After-hours: Mar 9, 2026, 7:58 PM EDT
Incannex Healthcare Revenue
In the fiscal year ending June 30, 2025, Incannex Healthcare had annual revenue of $86.00K with 616.67% growth.
Revenue (ttm)
$86.00K
Revenue Growth
+616.67%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
50.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 86.00K | 74.00K | 616.67% |
| Jun 30, 2024 | 12.00K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 539.05K | -883.65K | -62.11% |
| Jun 30, 2021 | 1.42M | 1.01M | 240.67% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Assertio Holdings | 137.35M |
| Rockwell Medical | 75.58M |
| InterCure | 72.16M |
| Aytu BioPharma | 62.64M |
| Cumberland Pharmaceuticals | 41.28M |
| Zhengye Biotechnology Holding | 21.46M |
| SCYNEXIS | 20.60M |
| TherapeuticsMD | 2.80M |
IXHL News
- 12 days ago - Incannex Announces Reverse Stock Split - GlobeNewsWire
- 19 days ago - Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026 - Newsfile Corp
- 5 weeks ago - Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board - GlobeNewsWire
- 6 weeks ago - Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program - GlobeNewsWire
- 7 weeks ago - Incannex Healthcare Wins Research and Development Award for Obstructive Sleep Apnea Program in the 2025 Clinical Trials Arena Excellence Awards - GlobeNewsWire
- 7 weeks ago - Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026 - GlobeNewsWire
- 3 months ago - Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA) - GlobeNewsWire
- 3 months ago - Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2026 - Newsfile Corp